Phaseline

Companies › Orum Therapeutics USA

Orum Therapeutics USA: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ORM-1153
anti-CD123 antibody-drug conjugate
IL3RAPhase 1CD123+ Acute Myeloid LeukemiaDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07809906ORM-1153Phase 1CD123+ Acute Myeloid LeukemiaOncologyDec 2028

Targets

IL3RA (1)

Companies with the same targets

AbbVie Aptevo Therapeutics Stemline Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.